Siegall Clay B's Form 4 filing
Immunome Inc.IMNM · filed Nov 25, 2024
- Accession no.
- 0001415889-24-027601
- Filed
- Nov 25, 2024
- Trade date
- Nov 21-22, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market purchases total $962.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Siegall Clay BCIK 0001167496 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The weighted average purchase price for the transaction report was $9.5412, and the range of prices were between $9.41 and 9.68. Upon request be the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
Referenced by the price of 1 transaction in Table I.
- F2
The weighted average purchase price for the transaction report was $9.7787, and the range of prices were between $9.41 and $9.90. Upon request be the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
Referenced by the price of 1 transaction in Table I.